NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said a battle is brewing between Gilead Sciences (GILD - Get Report) and Express Scripts (ESRX - Get Report).
Gilead developed what he called a "wonder drug," referring to its hepatitis C pill, Sovaldi.
Express Scripts, an AAP holding, is trying to force Gilead to cut its prices, saying insurance companies don't want to pay so much for patients to get the treatment.
In the end, "Gilead wins this fight," Cramer argued. He reasoned that Sovaldi is a cure to a fatal disease. That alone is worth "a great deal" to the insurance companies because without the treatment, insurers have to pay the health costs for maintaining these patients, which is expensive.Gilead has been one of the weakest stocks in the market, he said, adding he's unsure if it will bottom on Tuesday. However, he maintains that Gilead is a "wonder company."
-- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts